1. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Dis 1990;18:259-266.

2. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. 1994;[submitted].

3. Anokhin KV, Mileusnic R, Shamakina IY, Rose SP. Effects of early experience on c-fos gene expression in the chick forebrain. Brain Res 1991;544:101-107.

4. Antelman SM, Eichler AJ, Black CA, Kocan D. Interchangeability of stress and amphetamine in sensitization. Science 1980;207:329-331.

5. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985;42:1193-1204.

6. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry 1988;145:1526-1531.

7. Banki C, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992;2:107-113.

8. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990;47:435-440.

9. Berridge MJ. The Albert Lasker Medical Awards. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA 1989;262:1834-1841.

10. Brown EE, Fibiger HC. Cocaine-induced conditioned locomotion: absence of associated increases in dopamine release. Neuroscience 1992;48:621-629.

11. Brown EE, Robertson GS, Fibiger HC. Evidence for conditional neuronal activation following exposure to a cocaine-paired environment: role of forebrain limbic structures. J Neurosci 1992;12:4112-4121.

12. Clark M, Post RM, Weiss SRB, Cain CJ, Nakajima T. Regional expression of c-fos mRNA in rat brain during the evolution of amygdala-kindled seizures. Mol Brain Res 1991;11:55-64.

13. Dubovsky SL, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992;149:118-120.

14. Engel J Jr. Molecular neurobiology of epilepsy. New York: Elsevier, 1992.

15. Fontana DJ, Post RM, Pert A. Conditioned increase in mesolimbic dopamine overflow by stimuli associated with cocaine. Brain Res 1993;629:31-39.

16. Geinisman Y, de Toledo-Morrell L, Morrell F. The brain's record of experience: kindling-induced enlargement of the active zone in hippocampal perforated synapses. Brain Res 1990;513:175-179.

17. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493.

18. George MS, Jones M, Post RM, Mikalauskas K, Leverich GS. The longitudinal course of affective illness: mathematical models involving chaos theory. World Congr Biol Psychiatry Abstracts 1992;31:86-87A(abst 58).

19. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295-330.

20. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 1990;87:6912-6916.

21. Herkenham M. Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience 1987;23:1-38.

22. Himmelhoch JM, Garfinkel ME. Sources of lithium resistance in mixed mania. Psychopharmacol Bull 1986;22:613-620.

23. Hoschl C. Do calcium antagonists have a place in the treatment of mood disorders. Drugs 1991;42:721-729.

24. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-251.

25. Kalivas PW, Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 1990;5:45-58.

26. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. dopamine axon terminals. J Neurosci 1993;13:266-275.

27. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991;16:223-244.

28. Keck PE Jr, McElroy SL, Vuckovic A, Friedman LM. Combined valproate and carbamazepine treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:319-322.

29. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of literature. J Clin Psychopharmacol 1992;12:276-281.

30. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: Livingstone; 1921. Barclay RM, Robertson GM, translators.

31. Kramlinger KG, Post RM. Ultra-rapid and ultradian cycling in bipolar affective illness. 1994;[submitted].

32. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatria Neuropsychopharmakol 1980; 13:156-167.

33. Lieberman JA, Mayerhoff DI, Loebel A, Geisler S, Alvir J. Evidence for sensitization in early stage of schizophrenia. Clin Neuropharmacol 1992;15(Suppl):54B.

34. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berl) 1989;98:535-538.

35. Margolis RL, Chuang D-M, Post RM. Programmed cell death: implications for neuropsychiatric disorders. Biol Psychiatry 1994;[in press].

36. Moratalla R, Robertson HA, Graybiel AM. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J Neurosci 1992;12:2609-2622.

37. Nakajima T, Daval JL, Gleiter CH, Deckert J, Post RM, Marangos PJ. c-Fos mRNA expression following electrical-induced seizure and acute nociceptive stress in mouse brain. Epilepsy Res 1989;4:156-159.

38. Nemeroff CB, Widerlov E, Bissette G. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344.

39. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123-129.

40. Okuma T. Effects of carbamazepine and other anticonvulsant drugs on affective disorders. Neuropsychobiology 1993;27:138-145.

41. Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:76-81.

42. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res [in press].

43. Pinel JPJ. Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: a double dissociation. Pharmacol Biochem Behav 1983;18:61-63.

44. Post RM. Alternatives to lithium for bipolar affective illness. In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Review of psychiatry, vol. 9. Washington DC: American Psychiatric Press; 1990:170-202.

45. Post RM. Prophylaxis of bipolar affective disorders. Int Rev Psychol 1990;2:277-320.

46. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.

47. Post RM, Kramlinger KG, Altshuler LL, Ketter TA, Denicoff K. Treatment of rapid cycling bipolar illness. Psychopharmacol Bull 1990;26:37-47.

48. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium discontinuation-induced refractoriness: Preliminary observations. Am J Psychiatry 1992;149:1727-1729.

49. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds. Lithium in medicine and biology. Lancashire, UK: Marius Press; 1993:71-84.

50. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders. A focus on long-term followup. J Clin Psychopharmacol 1990;10:318-327.

51. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitization in the longitudinal course of affective illness. Br J Psychiatry 1986;149:191-201.

52. Post RM, Weiss SRB. Endogenous biochemical abnormalities in affective illness: therapeutic vs. pathogenic. Biol Psychiatry 1992;32:469-484.

53. Post RM, Weiss SRB, Chuang D-M. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992;12:23S-35S.

54. Post RM, Weiss SRB, Fontana D, Pert A. Conditioned sensitization to the psychomotor stimulant cocaine. Ann NY Acad Sci 1992;654:386-399.

55. Post RM, Weiss SRB, Pert A. Animal models of mania. In: Willner P, Scheel-Kruger J, eds. The mesolimbic dopamine system: from motivation to action. Chichester: John Wiley; 1991:443-472.

56. Post RM, Weiss SRB, Rosen J, Smith M, Thomas N, Pert A. Co-morbidity of cocaine abuse and affective disorders. Am J Psychiatry [submitted].

57. Racine RJ. Modification of seizure activity by electrical stimulation. I. After-discharge threshold. Electroencephalogr Clin Neurophysiol 1972;32:269-279.

58. Rasmussen H. The cycling of calcium as an intracellular messenger. Sci Am 1989;261:66-73.

59. Rawlings SR, Hoyland J, Mason WT. Calcium homeostasis in bovine somatotrophs: calcium oscillations and calcium regulation by growth hormone-releasing hormone and somatostatin. Cell Calcium 1991;12:403-414.

60. Rosen JB, Abramowitz J, Post RM. Co-localization of TRH mRNA and Fos-like immunoreactivity in limbic structures following amygdala kindling. Mol Cell Neurosci 1993;4:335-342.

61. Rosen JB, Cain CJ, Weiss SRB, Post RM. Alterations in mRNA of enkephalin, dynorphin and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study. Mol Brain Res 1992;15:247-255.

62. Rouillon F. Adverse drug reaction in long term antidepressant treatment. Eur Neuropsychopharmacol 1991;1:216-218.

63. Roy-Byrne PP, Uhde TW, Post RM. Antidepressant effects of one night's sleep deprivation: clinical and theoretical implications. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins; 1984:817-835.

64. Rubinow DR, Post RM, Davis CL. Somatostatin. In: Nemeroff CB, ed. Neuropeptides and psychiatric disorders. Washington, DC: American Psychiatric Press; 1991:30-49.

65. Sakai S, Baba H, Sato M, Wada JA. Effect of DN-1417 on photosensitivity and cortically kindled seizure in Senegalese baboons, Papio papio. Epilepsia 1991;32:16-21.

66. Smith M, Weiss SRB, Abedin T, Post RM, Gold P. Effects of amygdala-kindling and electroconvulsive seizures on the expression of corticotropin releasing hormone (CRH) mRNA in the rat brain. Mol Cell Neurosci 1991;2:103-116.

67. Smith MA, Banerjee S, Gold PW, Glowa J. Induction of c-fos mRNA in rat brain by conditioned and unconditioned stressors. Brain Res 1992;578:135-141.

68. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088.

69. Sutula TP, Golarai G, Cavazos J. Assessing the functional significance of mossy fiber sprouting. Epilepsy Res Suppl 1992;7:251-259.

70. Wehr TA, Goodwin FK. Do antidepressants cause mania? Psychopharmacol Bull 1987;23:61-65.

71. Weiss SRB, Post RM. Contingent tolerance to carbamazepine: a peripheral-type benzodiazepine mechanism. Eur J Pharmacol 1991;193:159-163.

72. Weiss SRB, Post RM. Development and reversal of conditioned inefficacy and tolerance to the anticonvulsant effects of carbamazepine. Epilepsia 1991;32:140-145.

73. Weiss SRB, Post RM. Sensitization and kindling: the hidden liabilities of cocaine. Scientific Am [in press].

74. Weiss SRB, Post RM, Anthony P, Ferrer J. Contingent tolerance to carbamazepine is not affected by calcium-channel or NMDA-receptor blockers. Pharmacol Biochem Behav 1993;45:439-443.

75. Weiss SRB, Post RM, Costello M, Nutt DJ, Tandeciarz S. Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine's effects on hyperactivity and stereotypy. Neuropsychopharmacology 1990;3:273-281.

76. Weiss SRB, Post RM, Pert A, Woodward R, Murman D. Context-dependent cocaine sensitization: differential effect of haloperidol on development versus expression. Pharmacol Biochem Behav 1989;34:655-661.

77. Weiss SRB, Post RM, Sohn E, Berger A, Lewis R. Cross tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Res [in press].

78. White FJ, Henry DJ, Hu X-T, Jeziorski M, Ackerman JM. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system. In: Lakoski JM, Galloway MP, White FJ, eds. Cocaine: pharmacology, physiology and clinical strategies. West Caldwell, NJ: Telford Press, 1992:261-293.

79. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990;147:14-21.

80. Yatsugi S, Yamamoto M. Anticonvulsive properties of YM-14673, a new TRH analogue, in amygdaloid-kindled rats. Pharmacol Biochem Behav 1991;38:669-672.

81. Young ST, Porrino LJ, Iadarola MJ. Cocaine induces striatal c-fos immunoreactive proteins via dopaminergic D1 receptors. Proc Natl Acad Sci USA 1991;88:1291-1295.

Back to Chapter